Literature DB >> 25469530

Increase of RT-related transmitted drug resistance in non-CRF01_AE among HIV type 1-infected men who have sex with men in the 7 cities of China.

Bin Zhao1, Xiaoxu Han, Junjie Xu, Qinghai Hu, Zhenxing Chu, Jing Zhang, Lin Lu, Zhe Wang, Jihua Fu, Xi Chen, Hongjing Yan, Minghua Zhuang, Lin Wang, Amy Sun, Christiana Meng Zhang, Hong Shang.   

Abstract

OBJECTIVES: To elucidate new features in the prevalence of HIV-1 transmitted drug resistance (TDR) in men who have sex with men (MSM) in China.
METHODS: A total of 441 HIV-1-positive subjects were recruited from high-risk MSM populations in 7 cities across China between 2012 and 2013. Nucleotide sequences of 1.1-kb pol-RT regions were amplified and sequenced from 367 of the 441 samples. Phylogenetic and genetic drug-resistant analyses were performed.
RESULTS: The overall distribution of HIV-1 genotypes was as the following: CRF01_AE, 52.3%; CRF07_BC, 33.2%; 01/B recombinants, 6.0%; subtype B (United States-European), 3.8%; subtype B', 3.8%; and CRF08_BC, 0.8%. About 91.3% of the sequences clustered together. An overall 4.6% TDR rate was found. Reverse transcriptase (RT)-related TDR reached 2.7%. TDR of 2.2% was detected in protease region. Most of RT-related TDRs were detected in non-CRF01_AE subtypes (90.0%, 9/10), including T215A/S, K101E, K103N, V106M, and E138G. Most of the strains with TDRs (88.2%, 15/17) were presented in the clusters. TDR strains against non-nucleoside reverse transcriptase inhibitors in non-CRF01_AE subtypes also formed some subclusters (70.0%, 7/10). One CRF07_BC subject with K103N in Kunming had a very close genetic distance with one that received highly active antiretroviral therapy locally (bootstrap = 99%). Two CRF55_01B subjects carrying K103N in Changsha and Nanjing also had a very close genetic distance (bootstrap = 100%).
CONCLUSIONS: RT-related TDR of non-CRF01_AE became the main TDR among MSM in China. There is an increasing trend and a potential transmission risk for the RT-related TDR among MSM throughout China. Some TDRs could have already been transmitted among different cities. Intervention efforts should be strengthened among MSM to prevent further transmission of HIV and the proliferation of the strains with TDR.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25469530     DOI: 10.1097/QAI.0000000000000467

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  12 in total

1.  Drug resistance mutation profiles of the drug-naïve and first-line regimen-treated HIV-1-infected population of Suzhou, China.

Authors:  Tingting Li; Feng Qian; Ting Yuan; Weilu Xu; Li Zhu; Jinlong Huang; Haiyan Wang; Yueping Zhu; Yinling Wang; Xiaohong Li; Saihong Gu; Zhuqing Tan; Hui Chen; Xiangrong Luo; Wei Zhu; Wenjuan Lu; Ping Xu; Ming Li; Yuying Chen; Yong Gao; Rongge Yang; Chuanwu Zhu; Binlian Sun
Journal:  Virol Sin       Date:  2017-08-07       Impact factor: 4.327

2.  Cost-effectiveness of oral pre-exposure prophylaxis and expanded antiretroviral therapy for preventing HIV infections in the presence of drug resistance among men who have sex with men in China: A mathematical modelling study.

Authors:  Xinye Jin; Lingen Shi; Congyue Wang; Tao Qiu; Yi Yin; Mingwang Shen; Gengfeng Fu; Zhihang Peng
Journal:  Lancet Reg Health West Pac       Date:  2022-05-03

3.  Epidemiology and Clinical Outcomes of HIV Infection in South-Central China: A Retrospective Study From 2003 to 2018.

Authors:  Tingting Yue; Pan Zhang; Yuantao Hao; Jianmei He; Jun Zheng; Erik De Clercq; Guangdi Li; Yaxiong Huang; Fang Zheng
Journal:  Front Public Health       Date:  2022-06-09

4.  Internet-Based Sex-Seeking Behavior Promotes HIV Infection Risk: A 6-Year Serial Cross-Sectional Survey to MSM in Shenyang, China.

Authors:  Shi Pan; Jun-Jie Xu; Xiao-Xu Han; Jing Zhang; Qing-Hai Hu; Zhen-Xing Chu; Yan-Qiu Hai; Xiang Mao; Yan-Qiu Yu; Wen-Qing Geng; Yong-Jun Jiang; Hong Shang
Journal:  Biomed Res Int       Date:  2016-12-25       Impact factor: 3.411

5.  Epidemiological surveillance of HIV-1 transmitted drug resistance among newly diagnosed individuals in Shijiazhuang, northern China, 2014-2015.

Authors:  Xianfeng Wang; Xiaosong Liu; Feng Li; Hong Zhou; Jiefang Li; Yingying Wang; Lihua Liu; Shujun Liu; Yi Feng; Ning Wang
Journal:  PLoS One       Date:  2018-06-05       Impact factor: 3.240

6.  Natural polymorphisms in HIV-1 CRF01_AE strain and profile of acquired drug resistance mutations in a long-term combination treatment cohort in northeastern China.

Authors:  Zesong Sun; Jinming Ouyang; Bin Zhao; Minghui An; Lin Wang; Haibo Ding; Xiaoxu Han
Journal:  BMC Infect Dis       Date:  2020-02-26       Impact factor: 3.090

7.  Dynamics of HIV-1 Molecular Networks Reveal Effective Control of Large Transmission Clusters in an Area Affected by an Epidemic of Multiple HIV Subtypes.

Authors:  Mingchen Liu; Xiaoxu Han; Bin Zhao; Minghui An; Wei He; Zhen Wang; Yu Qiu; Haibo Ding; Hong Shang
Journal:  Front Microbiol       Date:  2020-11-13       Impact factor: 5.640

8.  Priority Intervention Targets Identified Using an In-Depth Sampling HIV Molecular Network in a Non-Subtype B Epidemics Area.

Authors:  Bin Zhao; Wei Song; Minghui An; Xue Dong; Xin Li; Lu Wang; Jianmin Liu; Wen Tian; Zhen Wang; Haibo Ding; Xiaoxu Han; Hong Shang
Journal:  Front Cell Infect Microbiol       Date:  2021-03-29       Impact factor: 5.293

9.  Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.

Authors:  Zhen Wang; Bin Zhao; Minghui An; Wei Song; Xue Dong; Xin Li; Lu Wang; Lin Wang; Wen Tian; Haibo Ding; Xiaoxu Han
Journal:  BMC Infect Dis       Date:  2021-07-09       Impact factor: 3.090

10.  Characterization of subtypes and transmitted drug resistance strains of HIV among Beijing residents between 2001-2016.

Authors:  Jingrong Ye; Mingqiang Hao; Hui Xing; Yuncong Wang; Juan Wang; Yi Feng; Ruolei Xin; Ji Zeng; Shuai Zhao; Yinxiao Hao; Jing Chen; Yuhua Ruan; Xue Li; Yiming Shao; Hongyan Lu
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.